{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:41:59Z","timestamp":1773265319462,"version":"3.50.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ad.2018.03.013","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T18:22:02Z","timestamp":1527963722000},"page":"584-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Consenso multidisciplinar sobre prevenci\u00f3n y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol\u00f3gico. Adaptaci\u00f3n al paciente dermatol\u00f3gico"],"prefix":"10.1016","volume":"109","author":[{"given":"P.","family":"Rodr\u00edguez-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mir-Viladrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chicharro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Solano-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"L\u00f3pez-Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Taxonera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Mart\u00ednez-Lacasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00eda-Gasalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arias-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dauden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2018.03.013_bib0605","unstructured":"Tuberculosis global report 2017. World Health Organization [consultado Sep 2017]. Disponible en: www.who.int\/tb"},{"key":"10.1016\/j.ad.2018.03.013_bib0610","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1468-3083.2010.03836.x","article-title":"Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: Report of a case series with 144 patients","volume":"25","author":"S\u00e1nchez-Moya","year":"2011","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2018.03.013_bib0615","first-page":"562","article-title":"What can we learn by following the development of tuberculosis from one generation to another? 1930","volume":"6","author":"Andvord","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib0620","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/oxfordjournals.aje.a112099","article-title":"A method for estimating the prevalence of tuberculosis infection","volume":"101","author":"Rust","year":"1975","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.ad.2018.03.013_bib0625","unstructured":"Infliximab approval process in Crohn's disease. Deparment of Health and Human Services. Public Health Service. Food and Drug Administration; August 24, 1998."},{"issue":"Suppl I","key":"10.1016\/j.ad.2018.03.013_bib0630","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2009.123885","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009","volume":"69","author":"Furst","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib0635","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2018.03.013_bib0640","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2018.03.013_bib0645","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/jdv.12011","article-title":"Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry","volume":"27","author":"S\u00e1nchez-Moya","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2018.03.013_bib0650","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0210-5705(03)70338-0","article-title":"Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab CB Spanish Working Group on Crohn Disease and Ulcerative Colitis","volume":"26","author":"Obrador","year":"2003","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0655","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib0660","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.ad.2018.03.013_bib0665","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2018.03.013_bib0670","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Jauregui-Amezaga","year":"2013","journal-title":"J Crohn Colitis."},{"key":"10.1016\/j.ad.2018.03.013_bib0675","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ad.2018.03.013_bib0680","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arbres.2015.04.016","article-title":"Consensus document on prevention and treatment of tuberculosis in patients for biological treatment","volume":"52","author":"Mir-Viladrich","year":"2016","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.ad.2018.03.013_bib0685","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","article-title":"Purpose of quality standards for infectious diseases","volume":"18","author":"Gross","year":"1994","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.ad.2018.03.013_bib0690","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eimc.2010.02.006","article-title":"Documento de consenso sobre diagn\u00f3stico, tratamiento y prevenci\u00f3n de la tuberculosis","volume":"28","author":"Gonzalez-Mart\u00edn","year":"2010","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.ad.2018.03.013_bib0695","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Remicade (infliximab) [consultado Sep 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000240\/WC500050888.pdf"},{"key":"10.1016\/j.ad.2018.03.013_bib0700","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Enbrel (etanercept) [consultado Sep 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf"},{"key":"10.1016\/j.ad.2018.03.013_bib0705","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Humira (adalimumab) [consultado Sep 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf"},{"key":"10.1016\/j.ad.2018.03.013_bib0710","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Stelara (ustekinumab) [consultado Sep 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000958\/WC500058513.pdf"},{"key":"10.1016\/j.ad.2018.03.013_bib0715","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Cosentyx (secukinumab) [consultado Sep 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/003729\/WC500183129.pdf"},{"key":"10.1016\/j.ad.2018.03.013_bib0720","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Taltz (ixekizumab) [consultado Sep 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/003943\/WC500205804.pdf"},{"key":"10.1016\/j.ad.2018.03.013_bib0725","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/17469872.2013.814880","article-title":"Etanercept for the treatment of psoriasis","volume":"8","author":"Ara","year":"2013","journal-title":"Expert Rev Dermatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0730","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1610-0387.2007.06319.x","article-title":"The use of infliximab in dermatology","volume":"5","author":"Rott","year":"2007","journal-title":"J Dtsch Dermatol Ges."},{"key":"10.1016\/j.ad.2018.03.013_bib0735","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.sder.2010.02.004","article-title":"The future of biological therapies","volume":"29","author":"Warren","year":"2010","journal-title":"Semin Cutan Med Surg."},{"key":"10.1016\/j.ad.2018.03.013_bib0740","doi-asserted-by":"crossref","first-page":"e51819","DOI":"10.1371\/journal.pone.0051819","article-title":"Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity","volume":"7","author":"Tsuda","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.ad.2018.03.013_bib0745","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2018.03.013_bib0750","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase ii and iii clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2018.03.013_bib0755","first-page":"S170","article-title":"Efficacy of ixekizumab therapy: Integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3","volume":"136","author":"Papp","year":"2016","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2018.03.013_bib0760","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.ad.2018.03.013_bib0765","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for Psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Eng J Med."},{"key":"10.1016\/j.ad.2018.03.013_bib0770","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Eng J Med."},{"key":"10.1016\/j.ad.2018.03.013_bib0775","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2018.03.013_bib0780","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12507","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","author":"Fioranelli","year":"2017","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2018.03.013_bib0785","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2018.03.013_bib0790","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0761-8425(08)75089-7","article-title":"Tuberculose, agents anti-TNF et autres immunosuppresseurs: \u00c9volution des strat\u00e9gies de pr\u00e9vention","volume":"25","author":"Liot\u00e9","year":"2008","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.ad.2018.03.013_bib0795","author":"Manadan","year":"2002","journal-title":"Tuberculosis and etanercept. Proceedings of American College of Rheumatology Conference"},{"key":"10.1016\/j.ad.2018.03.013_bib0800","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1128\/CVI.00401-07","article-title":"Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients","volume":"155","author":"Newton","year":"2008","journal-title":"Clin Vaccine Immunol."},{"key":"10.1016\/j.ad.2018.03.013_bib0805","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: Another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ad.2018.03.013_bib0810","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society of Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib0815","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2012.11162.x","article-title":"A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial","volume":"168","author":"Tsai","year":"2012","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2018.03.013_bib0820","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/archdermatol.2012.2958","article-title":"Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment","volume":"148","author":"S\u00e1nchez-Moya","year":"2012","journal-title":"Arch Dermatol."},{"issue":"Suppl 2","key":"10.1016\/j.ad.2018.03.013_bib0825","first-page":"432","article-title":"FRI0025 no reactivation of dormant Mycobacterium tuberculosis in human in vitro granuloma model after anti-IL-17A treatment, in contrast to anti-TNF \u03b1 treatment","volume":"75","author":"Kapoor","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2018.03.013_bib0830","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jdermsci.2016.08.198","article-title":"Comparison of anti-IL-17A, IL-17F and TNF-\u03b1 antibodies on host resistance to acute Mycobacterium tuberculosis infection in mice","volume":"84","author":"Kammueller","year":"2016","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.ad.2018.03.013_bib0835","first-page":"e152","article-title":"Secukinumab treatment shows no evidence for reactivation of previous or latent TB infection in subjects with psoriasis: A pooled phase 3 safety analysis","volume":"72","author":"Kamm\u00fcller","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0840","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8 T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans","volume":"119","author":"Bruns","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ad.2018.03.013_bib0845","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.282.5386.121","article-title":"An antimicrobial activity of cytolytic T cells mediated by granulysin","volume":"282","author":"Stenger","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ad.2018.03.013_bib0850","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.276.5319.1684","article-title":"Differential effects of cytolytic T cell subsets on intracellular infection","author":"Stenger","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ad.2018.03.013_bib0855","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1189\/jlb.0607426","article-title":"XCLI (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infeciton with Mycobacterium tuberculosis negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability","volume":"82","author":"Ordway","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ad.2018.03.013_bib0860","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4","article-title":"Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells","volume":"30","author":"Van Pinxteren","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ad.2018.03.013_bib0865","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1164\/rccm.200503-411OC","article-title":"Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts","volume":"173","author":"Carranza","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ad.2018.03.013_bib0870","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.immuni.2008.06.011","article-title":"Tumor necrosis factors signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death","volume":"29","author":"Clay","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ad.2018.03.013_bib0875","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2018.03.013_bib0880","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0885","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2018.03.013_bib0890","first-page":"1127","article-title":"TB in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib0895","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.11134","article-title":"TB in the cytokine era: What rheumatologist need to know","volume":"48","author":"Hamilton","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2018.03.013_bib0900","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e3283025ec2","article-title":"Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: Diagnostic and therapeutic strategies","volume":"20","author":"Keane","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0905","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00296-016-3575-3","article-title":"Reinitiation of biologics after the development of tuberculosis under anti-TNF therapy","volume":"36","author":"Ozguler","year":"2016","journal-title":"Rheumat Int."},{"key":"10.1016\/j.ad.2018.03.013_bib0910","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1469-0691.2007.01891.x","article-title":"Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-\u03b1 antagonist therapy: Safe re-initiation of TNF-\u03b1 blockers after appropriate anti-tuberculous treatment","volume":"14","author":"Denis","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ad.2018.03.013_bib0915","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/art.23210","article-title":"Is it safe to readminister tumor necrosis factor \u03b1 antagonists following tuberculosis flare?","volume":"58","author":"Aslanidis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ad.2018.03.013_bib0920","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ad.2015.10.004","article-title":"Screening for latent tuberculosis in the patient with moderate to severe psoriasis who is a candidate for systemic and\/or biologic therapy","volume":"107","author":"Mart\u00ednez-L\u00f3pez","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2018.03.013_bib0925","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis","volume":"64","author":"Ponce de Leon","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib0930","first-page":"776","article-title":"Comparison of an interferon-\u03b3 assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population","volume":"35","author":"Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0935","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","article-title":"The tuberculin skin test","volume":"17","author":"Huebner","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib0940","unstructured":"Cellestis. Quantiferon-TB Gold. 2009 [consultado 20 oct 2009]. Disponible en: hhttp:\/\/www.cellestis.com\/"},{"key":"10.1016\/j.ad.2018.03.013_bib0945","unstructured":"OxfordImmunotec. T. Spot-TB. 2009 [consultado 20 oct 2009]. Disponible en: http:\/\/www.oxfordimmunotec.com\/"},{"key":"10.1016\/j.ad.2018.03.013_bib0950","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/CVI.00364-07","article-title":"Comparison of two commercially available gamma-interferon blood tests for immunodiagnosis of tuberculosis","volume":"15","author":"Dominguez","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.ad.2018.03.013_bib0955","first-page":"1","article-title":"Updated guidelines for using interferon g release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.ad.2018.03.013_bib0960","unstructured":"European Centre for Disease Prevention and Control (ECDC). Use of interferon-gamma release assays in support of TB diagnosis [consultado 7 jul 2013]. Disponible en: http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/1103_GUI_IGRA.pdf"},{"key":"10.1016\/j.ad.2018.03.013_bib0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032482","article-title":"Interferon-\u03b3 release assay for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: A systematic review and metaanalysis","author":"Santin","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.ad.2018.03.013_bib0970","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.arbres.2016.02.020","article-title":"Executive summary of the guidelines for the use of interferon-gamma release assays in the diagnosis of tuberculosis infection","volume":"52","author":"Santin","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.ad.2018.03.013_bib0975","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1157\/13126836","article-title":"Normativa SEPAR. Diagn\u00f3stico y tratamiento de la tuberculosis","volume":"44","author":"Ruiz Manzano","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.ad.2018.03.013_bib0980","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.eimc.2012.06.014","article-title":"Use of Quantiferon-TB-Gold in Tube\u00ae test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice","volume":"31","author":"Garc\u00eda-Gasalla","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ad.2018.03.013_bib0985","first-page":"770","article-title":"Comparison of an in vitro tuberculosis interferon-\u03b3 assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: A pilot study in rheumatoid arthritis","volume":"35","author":"Greenberg","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0990","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3899\/jrheum.090268","article-title":"Agreement between Quantiferon-TB Gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"36","author":"Inanc","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2018.03.013_bib0995","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10096-008-0519-1","article-title":"Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment","volume":"27","author":"Bocchino","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1000","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/rheumatology\/kem064","article-title":"Use of Quantiferon TB Gold test as a part of a screening progrmme in patients with RA under consideration for treatment with antiTNF-alpha agents: The Newcastle (UK) experience","volume":"46","author":"Pratt","year":"2007","journal-title":"Rheumatology."},{"key":"10.1016\/j.ad.2018.03.013_bib1005","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-007-0361-2","article-title":"Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration","volume":"27","author":"Takahashi","year":"2007","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.ad.2018.03.013_bib1010","first-page":"1464","article-title":"Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment","volume":"35","author":"Vassilopoulos","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2018.03.013_bib1015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1020","first-page":"117","article-title":"Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers","volume":"11","author":"Cobanoglu","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1025","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/ard.2007.069799","article-title":"Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy","volume":"66","author":"Sellam","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/ers.09.20","article-title":"IFN-gamma release assay to diagnose TB infection in the immunocompromised individual","volume":"3","author":"Dominguez","year":"2009","journal-title":"Expert Rev Respir Med."},{"key":"10.1016\/j.ad.2018.03.013_bib1035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.200811-1704OC","article-title":"Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing","volume":"180","author":"Van Zyl-Smit","year":"2009","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.ad.2018.03.013_bib1040","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-3083.2008.02103.x","article-title":"The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays","volume":"67","author":"Vilaplana","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.ad.2018.03.013_bib1045","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/apt.12037","article-title":"Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-a inhibitors","volume":"36","author":"Papay","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2018.03.013_bib1050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2011-200489","article-title":"Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFa inhibitors: The utility of IFNg assay","volume":"71","author":"Chen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1055","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar3882","article-title":"Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor-alpha antagonists","volume":"14","author":"Hatemi","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ad.2018.03.013_bib1060","doi-asserted-by":"crossref","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"10.1016\/j.ad.2018.03.013_bib1065","first-page":"1441","article-title":"Clinical practice","volume":"364","author":"Horsburgh","year":"2011","journal-title":"Latent tuberculosis infection in the United States. N Engl J Med"},{"key":"10.1016\/j.ad.2018.03.013_bib1070","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1075","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1080","first-page":"735","article-title":"Update: Adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-- United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.ad.2018.03.013_bib1085","unstructured":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60:555-564."},{"key":"10.1016\/j.ad.2018.03.013_bib1090","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ad.2018.03.013_bib1095","first-page":"e211","article-title":"Isoniazid therapy for latent tuberculosis in psoriasis patients receiving biological agents: Is it safe and efficacious?","volume":"53","author":"S\u00e1nchez-Moya","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2018.03.013_bib1100","first-page":"504","article-title":"Peripheral neuritis in tuberculous patients treated with isoniazid","volume":"70","author":"Oestreicher","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"10.1016\/j.ad.2018.03.013_bib1105","first-page":"398","article-title":"Impact of a shortage of first-line antituberculosis medication on tuberculosis control, United States, 2012-2013","volume":"24","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.ad.2018.03.013_bib1110","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1164\/ajrccm.155.5.9154885","article-title":"Rifampin preventive therapy for tuberculosis infection: Experience with 157 adolescents","volume":"155","author":"Villarino","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ad.2018.03.013_bib1115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial","volume":"18","author":"Menzies","year":"2008","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.ad.2018.03.013_bib1120","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ad.2018.03.013_bib1125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.ad.2018.03.013_bib1130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/COH.0b013e3282fbaad0","article-title":"Interactions between antiretroviral agents and those used to treat tuberculosis","volume":"3","author":"Bonora","year":"2008","journal-title":"Curr Opin HIV AIDS."},{"key":"10.1016\/j.ad.2018.03.013_bib1135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5588\/ijtld.12.0510","article-title":"Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population","volume":"17","author":"Jim\u00e9nez-Fuentes","year":"2013","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.ad.2018.03.013_bib1140","doi-asserted-by":"crossref","first-page":"e36001","DOI":"10.1371\/journal.pone.0036001","article-title":"The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in Southern India: A trial-based analysis","volume":"7","author":"Pho","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.ad.2018.03.013_bib1145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11904-012-0120-1","article-title":"Treatment of latent tuberculosis infection in HIV: Shorter or longer?","volume":"9","author":"Person","year":"2012","journal-title":"Curr HIV\/AIDS Rep."},{"key":"10.1016\/j.ad.2018.03.013_bib1150","first-page":"133","article-title":"Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)","volume":"66","author":"Schaberg","year":"2012","journal-title":"Pneumologie."},{"key":"10.1016\/j.ad.2018.03.013_bib1155","doi-asserted-by":"crossref","first-page":"e30194","DOI":"10.1371\/journal.pone.0030194","article-title":"Strategies for treating latent multiple-drug resistant tuberculosis: A decision analysis","volume":"7","author":"Holland","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.ad.2018.03.013_bib1160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1183\/09059180.00000511","article-title":"Update on tuberculosis: TB in the early 21st century","volume":"20","author":"Connell","year":"2011","journal-title":"Eur Respir Rev."},{"key":"10.1016\/j.ad.2018.03.013_bib1165","first-page":"171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","volume":"20","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ad.2018.03.013_bib1170","first-page":"1433","article-title":"[Tuberculosis in HIV\/AIDS patients] [art\u00edculo en japon\u00e9s]","volume":"69","author":"Fujita","year":"2011","journal-title":"Nihon Rinsho."},{"key":"10.1016\/j.ad.2018.03.013_bib1175","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5114\/aoms.2013.33352","article-title":"Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-\u03b1 agents","volume":"9","author":"Paluch-Ole\u015b","year":"2013","journal-title":"Arch Med Sci."},{"key":"10.1016\/j.ad.2018.03.013_bib1180","first-page":"C4480","article-title":"Danish Society for Gastroenterology Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen","year":"2012","journal-title":"Dan Med J."},{"key":"10.1016\/j.ad.2018.03.013_bib1185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diagmicrobio.2010.12.020","article-title":"Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-\u03b3 release assay in patients considered for anti-tumor necrosis factor-\u03b1 therapy","volume":"71","author":"Casas","year":"2011","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.ad.2018.03.013_bib1190","first-page":"19","article-title":"Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: Systematic review","volume":"10","author":"Fraser","year":"2006","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.ad.2018.03.013_bib1195","first-page":"61","article-title":"TNF-alpha blockade and tuberculosis: Better look before you leap","author":"Breevbeld","year":"2003","journal-title":"Ned J Med"},{"key":"10.1016\/j.ad.2018.03.013_bib1200","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2012-201979","article-title":"You can\u2019t always get what you want, but if you try sometimes (with two tests \u2014TST and IGRA\u2014for tuberculosis) you get what you need","volume":"71","author":"Winthrop","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731018301790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731018301790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:07:47Z","timestamp":1757552867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731018301790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":120,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0001731018301790"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2018.03.013","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consenso multidisciplinar sobre prevenci\u00f3n y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol\u00f3gico. Adaptaci\u00f3n al paciente dermatol\u00f3gico","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2018.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}